Liberty Shoes manufactures and sells a wide variety of footwear and lifestyle accessories across India through a network of over 450 exclusive retail stores, wholesale distributors, and online platforms.
While the company possesses a legacy brand name, it fails to translate this into a competitive advantage as evidenced by low net margins (2.4%) and a ROCE (9.1%) that barely covers the cost of capital. The footwear market is highly fragmented, and the company lacks the pricing power or scale efficiency to differentiate itself from competitors.
Capital allocation is poor, characterized by stagnant EPS growth (-1.3% CAGR) despite rising revenues, indicating that reinvested earnings are not generating incremental value. The company carries a significant debt load relative to its thin margins, and interest coverage is uncomfortably low at 1.6x.
By 2029, the investment collapsed as the 2028 expiration of brand usage rights arrived without a favorable resolution, leaving the listed entity without its core identity. The ongoing legal warfare between promoter groups paralyzed strategic pivots, while the 1.6x interest coverage proved insufficient to weather a cyclical downturn in consumer spending. The combination of stagnant earnings, high debt service, and the siphoning of capital through royalty payments to promoter-owned firms eventually forced a restructuring that wiped out minority shareholders.
RichFakir rates Liberty Shoes Ltd's business quality as poor — 37/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Liberty Shoes Ltd is trading about 88% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Liberty Shoes Ltd is: Not rated. A poor business at an expensive price — it does not make our shortlist right now.
RichFakir's educational estimate of Liberty Shoes Ltd's fair value is about ₹102 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →